Skip to main content
. Author manuscript; available in PMC: 2023 Feb 21.
Published in final edited form as: Chem Soc Rev. 2022 Feb 21;51(4):1212–1233. doi: 10.1039/d1cs00417d

Figure 2:

Figure 2:

A) Chemical structure of FDA approved drug oxaliplatin (OXP) which can act as ICD inducer. B-C) CRT translocation (post 4 h incubation) and HMGB1 release (300 μM, post 24 h incubation) in CT26 cells upon treatment with OXP. D) In vivo demonstration of ICD-mediated challenge-tumour growth inhibition by OXP. E) Effect on tumour growth when OXP is administered to immunodeficient (nu/nu) mice. Reproduced with permission from ref. 31 (Oncogene, 2010, 29, 482–491). Copyright © Nature Publishing Group.